1309205-42-2

Basic information

• Product Name: (E)-6-(3-oxo-3-(3-phenoxyazetidin-1-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one
• Synonyms: (E)-6-(3-oxo-3-(3-phenoxyazetidin-1-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one
• CAS NO: 1309205-42-2
• Molecular Weight: 349.389
• Mol File: 1309205-42-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (E)-6-(3-oxo-3-(3-phenoxyazetidin-1-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-6-(3-oxo-3-(3-phenoxyazetidin-1-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one(1309205-42-2)
• EPA Substance Registry System: (E)-6-(3-oxo-3-(3-phenoxyazetidin-1-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one(1309205-42-2)

Safety Data

• Hazardous Substances Data: 1309205-42-2(Hazardous Substances Data)

Upstream product

• 76263-18-8 3-phenorxyazetidine 
• 527758-08-3 (E)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylic acid 
• 82622-43-3 3-phenoxy-1-(diphenylmethyl)azetidine 
• 335031-10-2 6-bromo-2-oxo-1,2,3,4-tetrahydro-1,8-naphthyridine-3-carboxylic acid methyl ester 
• 301335-39-7 3-phenoxyazetidine hydrochloride salt 
• 129686-16-4 6-bromo-3,4-dihydro-1,8-naphthyridine-2(1H)-one 
• 335031-01-1 2-amino-5-bromo-3-(hydroxymethyl)pyridine 
• 527758-07-2 tert-butyl (E)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylate 
• 335033-38-0 2-amino-5-bromo-3-(bromomethyl)pyridine hydrobromide 
• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 23612-57-9 (2-amino-3-pyridinyl)methanol 

Relevant articles and documents

Discovery of azetidine based ene-amides as potent bacterial enoyl ACP reductase (FabI) inhibitors

A novel and potent series of ene-amides featuring azetidines has been developed as FabI inhibitors active against drug resistant Gram-positive pathogens particularly staphylococcal organisms. Most of the compounds from the series possessed excellent biochemical inhibition of Staphylococcus aureus FabI enzyme and whole cell activity against clinically relevant MRSA, MSSA and MRSE organisms which are responsible for significant morbidity and mortality in community as well as hospital settings. The binding mode of one of the leads, AEA16, in Escherichia coli FabI enzyme was determined unambiguously using X-ray crystallography. The lead compounds displayed good metabolic stability in mice liver microsomes and pharmacokinetic profile in mice. The in vivo efficacy of lead AEA16 has been demonstrated in a lethal murine systemic infection model.